We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27-1.97) in Spikevax and 1.16-fold (95% CI: 0.98- 1.37) in Comirnaty vaccinees. Nearly 60% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95% CI: 0.62-1.09) and Comirnaty (0.86; 95% CI: 0.65-1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95% CI: 0.13-0.62) and 0.51 (95% CI: 0.27-0.96), respectively.
|State||Published - Sep 2022|
Bibliographical noteFunding Information:
GRY reports institutional grant funding of studies not related to the current study from Pfizer, consulting/honoraria from Teva, MSD, Astrazeneca, Pfizer and Moderna. NB and YL report institutional grants from Pfizer. All other authors report no conflicts of interest.
© 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.